Safety of targeting ROR1 in primates with chimeric antigen receptor-modified T cells

Cancer Immunology Research

Volumn 3, Issue 2, 2015, Pages 206-216

  Berger, Carolina ^a,b   Sommermeyer, Daniel ^a   Hudecek, Michael ^c   Berger, Michael ^a   Balakrishnan, Ashwini ^a   Paszkiewicz, Paulina J ^d   Kosasih, Paula L ^a   Rader, Christoph ^e   Riddell, Stanley R ^a,b,d  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^e SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC ANTIGEN RECEPTOR; ROR1 PROTEIN; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG; CYTOKINE; LYMPHOCYTE ANTIGEN RECEPTOR; RECEPTOR TYROSINE KINASE LIKE ORPHAN RECEPTOR; ROR1 PROTEIN, HUMAN;

ADIPOCYTE; ADOPTIVE TRANSFER; ANIMAL CELL; ARTICLE; BONE MARROW; CELL SURFACE; CHIMERIC ANTIGEN RECEPTOR MODIFIED T CELL; EMBRYO DEVELOPMENT; HUMAN; HUMAN CELL; IMMUNORECEPTOR TYROSINE BASED ACTIVATION MOTIF; IMMUNOTHERAPY; LUNG; LYMPH NODE; NONHUMAN; PANCREAS; PRE B LYMPHOCYTE; PROTEIN EXPRESSION; T LYMPHOCYTE; ADOPTIVE IMMUNOTHERAPY; ADVERSE EFFECTS; ANIMAL; ANIMAL MODEL; BLOOD; CELL MOTION; CELL SURVIVAL; GENE VECTOR; GENETIC ENGINEERING; GENETIC TRANSDUCTION; GENETICS; IMMUNOLOGY; METABOLISM; PROCEDURES; RETROVIRIDAE; RHESUS MONKEY;

ANIMALS; CELL MOVEMENT; CELL SURVIVAL; CYTOKINES; GENETIC ENGINEERING; GENETIC VECTORS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; MACACA MULATTA; MODELS, ANIMAL; RECEPTOR TYROSINE KINASE-LIKE ORPHAN RECEPTORS; RECEPTORS, ANTIGEN, T-CELL; RETROVIRIDAE; T-LYMPHOCYTES; TRANSDUCTION, GENETIC;

EID: 84962304846     PISSN: 23266066     EISSN: 23266074     Source Type: Journal    
DOI: 10.1158/2326-6066.CIR-14-0163     Document Type: Article

References (50)

1. Turtle CJ, Hudecek M, Jensen MC, Riddell SR. Engineered T cells for anticancer therapy. Curr Opin Immunol 2012;24:633-9.
2. Sadelain M, Brentjens R, Riviere I. The basic principles of chimeric antigen receptor design. Cancer Discov 2013;3:388-98.
3. Barrett DM, Singh N, Porter DL, Grupp SA, June CH. Chimeric antigen receptor therapy for cancer. Annu Rev Med 2014;65:10.1-10.15.
4. Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011;3: 95ra73.
5. Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, Cowell LG, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med 2013; 5:177ra38.
6. Kochenderfer JN, Rosenberg SA. Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. Nat Rev Clin Oncol 2013;10: 267-76.
7. Lamers CH, Sleijfer S, van Steenbergen S, van Elzakker P, van Krimpen B, Groot C, et al. Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity. Mol Ther 2013;21:904-12.
8. Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 2010;18:843-51.
9. Masiakowski P, Carroll RD. A novel family of cell surface receptors with tyrosine kinase-like domain. J Biol Chem 1992;267:26181-90.
10. Katoh M, Katoh M. Comparative genomics on ROR1 and ROR2 orthologs. Oncol Rep 2005;14:1381-4.
11. Hudecek M, Schmitt TM, Baskar S, Lupo-Stanghellini MT, Nishida T, Yamamoto TN, et al. The B-cell tumor associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor. Blood 2010;116:4532-41.
12. Baskar S, Kwong KY, Hofer T, Levy JM, Kennedy MG, Lee E, et al. Unique cell surface expression of receptor tyrosine kinase ROR1 in human B-cell chronic lymphocytic leukemia. Clin Cancer Res 2008;14:396-404.
13. Dave H, Anver MR, Butcher DO, Brown P, Khan J, Wayne AS, et al. Restricted cell surface expression of receptor tyrosine kinase ROR1 in pediatric B-lineage acute lymphoblastic leukemia suggests targetability with therapeutic monoclonal antibodies. PLoS ONE 2012;7: e52655.
14. Zhang S, Chen L, Wang-Rodriguez J, Zhang L, Cui B, Frankel W, et al. The onco-embryonic antigen ROR1is expressed by a variety of human cancers. Am J Pathol 2012;181:1903-10.
15. Zhang S, Chen L, Cui B, Chuang HY, Yu J, Wang-Rodriguez J, et al. ROR1 is expressedinhuman breast cancer and associated with enhanced tumor-cell growth. PLoS ONE 2012;7:e31127.
16. Borcherding N, Kusner D, Liu GH, Zhang W. ROR1, an embryonic protein with an emerging role in cancer biology. Protein Cell 2014;5:496-502.
17. Bicocca VT, Chang BH, Masouleh BK, Muschen M, Loriaux MM, Druker BJ, et al. Crosstalk between ROR1 and the pre-B cell receptor promotes survival of t(1;19) acute lymphoblastic leukemia. Cancer Cell 2012;22:656-67.
18. Cui B, Zhang S, Chen L, Yu J, Widhopf GF, Fecteau JF, et al. Targeting ROR1 inhibits epithelial-mesenchymal transition and metastasis. Cancer Res 2013;73:3649-60.
19. Yamaguchi T, Yanagisawa K, Sugiyama R, Hosono Y, Shimada Y, Arima C, et al. NKX2-1/TITF1/TTF-1-induced ROR1 is required to sustain EGFR survival signaling in lung adenocarcinoma. Cancer Cell 2012;21:348-61.
20. Gentile A, Lazzari L, Benvenuti S, Trusolino L, Comoglio PM. Ror1 is a pseudokinase that is crucial for Met-driven tumorigenesis. Cancer Res 2011;71:3132-41.
21. Choudhury A, Derkow K, Daneshmanesh AH, Mikaelsson E, Kiaii S, Kokhaei P, et al. Silencing of ROR1 and FMOD with si RNA results in apoptosis of CLL cells. Br J Haematol 2010;151:327-35.
22. Widhopf GF, Cui B, Ghia EM, Chen L, Messer K, Shen Z, et al. ROR1 can interact with TCL1 and enhance leukemogenesis in Em-TCL1 transgenic mice. Proc Natl Acad Sci U S A 2014;111:793-8.
23. Matsuda T, Nomi M, Ikeya M, Kani S, Oishi I, Terashima T, et al. Expression of the receptor tyrosine kinase genes, Ror1 and Ror2, during mouse development. Mech Dev 2001;105:153-6.
24. Broome HE, Rassenti LZ, Wang HY, Meyer LM, Kipps TJ. ROR1 is expressed on hematogones (non-neoplastic human B-lymphocyte precursors) and a minority of precursor-B acute lymphoblastic leukemia. Leuk Res 2011; 35:1390-4.
25. Hudecek M, Lupo-Stanghellini MT, Kosasih PL, Sommermeyer D, Jensen MC, Rader C, et al. Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells. Clin Cancer Res 2013;19:3153-64.
26. Yang J, Baskar S, Kwong KY, Kennedy MG, Wiestner A, Rader C. Therapeutic potential and challenges of targeting receptor tyrosine kinase ROR1 with monoclonal antibodies in B-cell malignancies. PLoS ONE 2011;6:e21018.
27. Berger C, Berger M, Anderson DE, Riddell SR. A non-human primate model for analysis of safety, persistence, and function of adoptively transferred T cells. J Med Primatol 2011;40:88-103.
28. Berger C, Jensen MC, Lansdorp PM, Gough M, Elliott C, Riddell SR. Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. J Clin Invest 2008;118:294-305.
29. Leisegang M, Engels B, Meyerhuber P, Kieback E, Sommermeyer D, Xue S-A, et al. Enhanced functionality of T cell receptor-redirected T cells is defined by the transgene cassette. J Mol Med 2008;86:573-83.
30. Wang X, Chang W-C, Wong CW, Colcher D, Sherman M, Ostberg JR, et al. A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells. Blood 2011;118:1255-63.
31. Rettig MP, Ritchey JK, Meyerrose TE, Haug JS, Dipersio JF. Transduction and selection of human T cells with novel CD34/thymidine kinase chimeric suicide genes for the treatment of graft-versus-host disease. Mol Ther 2003;8:29-41.
32. Forouzesh F, Tabarian SS, Emami S, Tehrani M-J, Hadavi R, Rabbani H. Construction and stable expression of a truncated human receptor tyrosine kinase Ror1 (Ror1-ECD). Avicenna J Med Biotech 2012;4:41-5.
33. + T lymphocytes in rhesus macaques. J Immunol Methods 2007;325:20-34.
34. Berger C, Huang M-L, Gough M, Greenberg PD, Riddell SR, Kiem H-P. Nonmyeloablative immunosuppressive regimen prolongs in vivo persistence of gene-modified autologous T cells in a nonhuman primate model. J Virol 2001;75:799-808.
35. Riddell SR, Elliott M, Lewinsohn DA, Gilbert MJ, Wilson L, Manley SA, et al. T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nat Med 1996;2:216-23.
36. Ahn K, Huh J-W, Park S-J, Kim D-S, Ha H-S, Kim Y-J, et al. Selection of internal reference genes for SYBR green qRT-PCR studies ofrhesus monkey (Macaca mulatta) tissues. BMC Mol Biol 2008;9:78.
37. Pfaffl MW A new mathematical model for relative quantification in realtime RT-PCR. Nucleic Acids Res 2001;29:e45.
38. Maus MV, Grupp SA, Porter DL, June CH. Antibody modified T cells: CARs take the front seat for hematologic malignancies. Blood 2014; 123:2625-35.
39. McGeachin RL, Akin JR. Amylase levels in the tissue and body fluids of several primate species. Comp Biochem Physiol 1982;72A: 267-9.
40. Lee J-I, Shin J-S, Lee J-E, Jung W-Y, Lee G, Kim M-S, et al. Reference values of hematology, chemistry, electrolytes, blood gas, coagulation time, and urinalysis in the Chinese rhesus macaques (Macaca mulatta). Xenotransplant 2012;19:244-8.
41. Lefebvre HP, Laroute V, Braun JP, Lassourd V, Toutain PL. Non-invasive and quantitative evaluation of post-injection muscle damage by pharmacokinetic analysis of creatine kinase release. Vet Res 1996; 27:343-61.
42. Demberg T, Brocca-Cofano E, Xiao P, Venzon D, Vargas-Inchaustegui D, Lee EM, et al. Dynamics of memory B-Cell populations in blood, lymph nodes, and bone marrow during antiretroviral therapy and envelope boosting in simian immunodeficiency virus SIVmac251-infected rhesus macaques. J Virol 2012;86:12591-604.
43. Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. Nat Rev Immunol 2011;11:85-97.
44. Moser B, Loetscher P. Lymphocyte traffic control by chemokines. Nat Immunol 2001;2:123-8.
45. Di Stasi A, Tey S-K, Dotti G, Fujita Y, Kennedy-Nasser A, Martinez C, et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med 2011;365:1673-83.
46. Hong H, Stastny M, Brown C, Chang W-C, Ostberg JR, Forman SJ, et al. Diverse solid tumors expressing a restricted epitope of L1-CAM can be targeted by chimeric antigen receptor redirected T lymphocytes. J Immunother 2014;37:93-104.
47. Gan HK, Burgess AW, Clayton AHA, Scott AM. Targeting of a conformationally exposed, tumor-specific epitope of EGFR as a strategy for cancer therapy. Cancer Res 2012;72:2924-30.
48. Kandalaft L, Powell D, Coukos G. A phase I clinical trial of adoptive transfer of folate receptor-alpha redirected autologous T cells for recurrent ovarian cancer. J Transl Med 2012;10:157.
49. Tran E, Chinnasamy D, Yu Z, Morgan RA, Lee CCR, Restifo NP, et al. Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia. J Exp Med 2013; 210:1125-35.
50. Wang LC, Lo A, Scholler J, Sun J, Majumdar RS, Kapoor V, et al. Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity. Cancer Immunol Res 2014;2: 154-66.